These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24614082)

  • 1. Rapamycin rescues ABT-737 efficacy in small cell lung cancer.
    Gardner EE; Connis N; Poirier JT; Cope L; Dobromilskaya I; Gallia GL; Rudin CM; Hann CL
    Cancer Res; 2014 May; 74(10):2846-56. PubMed ID: 24614082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
    Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
    Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.
    Potter DS; Galvin M; Brown S; Lallo A; Hodgkinson CL; Blackhall F; Morrow CJ; Dive C
    Mol Cancer Ther; 2016 Jun; 15(6):1248-60. PubMed ID: 27197306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
    Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
    Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
    Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
    Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
    Kim KW; Moretti L; Mitchell LR; Jung DK; Lu B
    Clin Cancer Res; 2009 Oct; 15(19):6096-105. PubMed ID: 19773376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
    Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
    PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression.
    Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C
    Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo.
    Shen J; Xu L; Zhao Q
    Biochem Biophys Res Commun; 2016 May; 473(4):1170-1176. PubMed ID: 27073162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
    Mattoo AR; FitzGerald DJ
    Int J Cancer; 2013 Feb; 132(4):978-87. PubMed ID: 22821746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 modulation to activate apoptosis in prostate cancer.
    Bray K; Chen HY; Karp CM; May M; Ganesan S; Karantza-Wadsworth V; DiPaola RS; White E
    Mol Cancer Res; 2009 Sep; 7(9):1487-96. PubMed ID: 19737977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.